Literature DB >> 10698522

A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.

W L Blalock1, M Pearce, L S Steelman, R A Franklin, S A McCarthy, H Cherwinski, M McMahon, J A McCubrey.   

Abstract

The Raf/MEK/MAP kinase cascade plays a critical role in transducing growth signals from activated cell surface receptors. Using deltaMEK1:ER, a conditionally-active form of MEK1, we demonstrate the ability of this dual specificity protein kinase to abrogate the cytokine-dependency of the human and murine hematopoietic cells lines TF-1, FDC-P1 and FL5.12. Cytokine-independent cells were obtained from TF-1, FDC-P1 and FL5.12 cells at frequencies of 2.5 x 10(-3), 5 x 10(-5) and 10(-7) respectively, indicating that not all cells expressing deltaMEK1:ER were factor-independent. In general, cells that were converted to a cytokine-independent phenotype displayed a higher level of MAP kinase activity in response to deltaMEK1:ER activation than those that remained cytokine-dependent. deltaME-K1:ER-responsive cells could be maintained long-term in the presence of beta-estradiol as well as the estrogen-receptor antagonist 4-Hydroxy-Tamoxifen and the anti-estrogen ICI 164383. Removal of hormone led to the rapid cessation of cell growth in a manner similar to that observed when cytokine is withdrawn from the parental cells. Treatment of deltaMEKI:ER-responsive cells with a specific and selective inhibitor, PD98059, prevented growth in response to beta-estradiol. GM-CSF mRNA transcripts were detected in the MEK1-responsive cells indicating that the activated deltaMEK1:ER may induce a pathway leading to autocrine proliferation. Treatment of MEK1-responsive cells with an anti-GM-CSF antibody, but not a control antibody, suppressed cell growth. The cell lines described here will be useful for elaborating the ability of the MAP kinase pathway to regulate cell proliferation in hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698522     DOI: 10.1038/sj.onc.1203337

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

Review 2.  Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Authors:  Daniel E Johnson
Journal:  Adv Enzyme Regul       Date:  2007-11-19

3.  Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation.

Authors:  Amar M Singh; David Reynolds; Timothy Cliff; Satoshi Ohtsuka; Alexa L Mattheyses; Yuhua Sun; Laura Menendez; Michael Kulik; Stephen Dalton
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

4.  Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation.

Authors:  David Wan-Cheng Li; Jin-Ping Liu; Ying-Wei Mao; Hua Xiang; Juan Wang; Wei-Ya Ma; Zigang Dong; Helen M Pike; Rhoderick E Brown; John C Reed
Journal:  Mol Biol Cell       Date:  2005-07-06       Impact factor: 4.138

5.  Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.

Authors:  Maria Rosaria Ricciardi; Maria Cristina Scerpa; Paola Bergamo; Ludovica Ciuffreda; Maria Teresa Petrucci; Sabina Chiaretti; Simona Tavolaro; Maria Grazia Mascolo; Stephen L Abrams; Linda S Steelman; Twee Tsao; Antonio Marchetti; Marina Konopleva; Donatella Del Bufalo; Francesco Cognetti; Robin Foà; Michael Andreeff; James A McCubrey; Agostino Tafuri; Michele Milella
Journal:  J Mol Med (Berl)       Date:  2012-03-08       Impact factor: 4.599

Review 6.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.

Authors:  Eva Chung; Motonari Kondo
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

7.  Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.

Authors:  M Milella; S M Kornblau; Z Estrov; B Z Carter; H Lapillonne; D Harris; M Konopleva; S Zhao; E Estey; M Andreeff
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

Review 8.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Ellis W T Wong; Fumin Chang; Brian Lehmann; David M Terrian; Michele Milella; Agostino Tafuri; Franca Stivala; Massimo Libra; Jorg Basecke; Camilla Evangelisti; Alberto M Martelli; Richard A Franklin
Journal:  Biochim Biophys Acta       Date:  2006-10-07

9.  Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.

Authors:  Kyung Hee Lee; Myung Soo Hyun; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

10.  Activation of mitogen-activated protein kinase kinase (MEK)/extracellular signal regulated kinase (ERK) signaling pathway is involved in myeloid lineage commitment.

Authors:  Chia-Lin Hsu; Kazu Kikuchi; Motonari Kondo
Journal:  Blood       Date:  2007-05-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.